borderline significantp = 0.04
The percentages of DCs in tumor did not seem to vary in NSCLC patients with different disease stages, except possibly for CD141 + DCs which were more frequent in stage I compared to stage II NSCLC, although the p -value was borderline significant ( p = 0.04) and will need to be confirmed with a larger patient cohort ( Supplementary Figure 12 ).